X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/gsk-launches-once-daily-single-inhaler-triple-therapy-for-copd-patients/articleshow/91095214.cms
https://www.pharmaceutical-technology.com/news/ema-gsk-trelegy-asthma-refusal/
https://www.raps.org/news-and-articles/news-articles/2020/9/fda-approvals-roundup-detectnet-trelegy-ellipta-ni
http://www.pharmatimes.com/news/gsk_books_19_sales_growth_for_first_quarter_1339304
https://www.gsk.com/en-gb/media/press-releases/gsk-filing-accepted-by-european-medicines-agency-for-trelegy-ellipta-use-in-adult-patients-with-asthma/
https://www.reuters.com/article/us-astrazeneca-fasenra/astrazeneca-respiratory-business-gets-boost-from-3-drug-inhaler-results-idUSKCN1VI0KB
https://www.fiercepharma.com/pharma/astrazeneca-s-copd-triplet-breztri-rival-to-gsk-s-trelegy-nabs-first-nod-from-japan
https://www.fiercepharma.com/pharma/teva-s-shaved-2-5b-costs-out-3b-goal-seeks-2020-growth
http://www.pharmatimes.com/news/eu_expands_label_of_gskinnovivas_copd_inhaler_1259755
https://www.prnewswire.com/news-releases/theravance-biopharma-highlights-expanded-copd-indication-for-trelegy-ellipta-in-europe-300748103.html
https://www.fiercepharma.com/pharma/despite-tight-supply-gsk-s-shingrix-zooms-to-blockbuster-status
http://www.pmlive.com/pharma_news/az_rival_to_gsks_copd_drug_anoro_fails_head-to-head_test_1249945
https://endpts.com/hit-by-surprise-setback-astrazeneca-scrambles-to-explain-why-its-two-in-one-copd-inhaler-fails-to-beat-gsk-rival/
https://www.fiercepharma.com/pharma/gsk-trots-out-cost-cutting-drive-not-consumer-spin-q2-beats
https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-in-japan-for-once-daily-single-inhaler-triple-therapy-ffumecvi-for-patients-with-copd/
http://investor.inva.com/news-releases/news-release-details/once-daily-trelegy-ellipta-gains-expanded-indication-us
https://www.pharmacompass.com/pdf/news/glaxosmithklines-elebrato-ellipta-lfluticasone-furoate-umeclidinium-vilanterol-receives-approval-in-europe-1517032320.pdf
http://www.pharmatimes.com/news/gsks_anoro_ellipta_beats_bis_spiolto_respimat_in_copd_trial_1210339
http://www.pharmatimes.com/news/chmp_backs_13_treatments_for_eu_approval_1205544
http://www.pmlive.com/pharma_news/gsk_closes_in_on_eu_approval_for_triple_copd_therapy_1205641
http://www.reuters.com/article/us-gsk-copd-approval/gsks-three-in-one-inhaler-gets-positive-opinion-from-eu-agency-idUSKCN1BQ0M0
http://www.fiercepharma.com/manufacturing/gsk-opens-new-56-6m-vaccines-plant-scotland
https://www.pharmacompass.com/pdf/news/glaxosmithklines-rolufta-umeclidinium-receives-tentative-approval-in-europe-1490353867.pdf
http://www.fiercepharma.com/manufacturing/gsk-moves-forward-new-plant-scotland-for-ventolin-api
http://www.pharmatimes.com/news/eight_medicines_leap_towards_eu_approval_1185408
http://www.pharmatimes.com/news/gsk_files_triple_combo_for_copd_in_europe_1180010
http://www.pmlive.com/pharma_appointments/mereo_biopharma_appoints_cfo_1177604
http://www.pmlive.com/pharma_news/gsks_bexsero_vaccine_growing_fast,_despite_tight_supply_1174879
http://www.pmlive.com/pharma_news/gsks_triple_copd_therapy_tops_symbicort_in_phase_iii_trial_1044758
www.seekingalpha.com/article/3839766-will-glaxosmithklines-triple-therapy-combination-perform-market
http://portal.anvisa.gov.br/wps/content/anvisa+portal/anvisa/sala+de+imprensa/menu+-+noticias+anos/2015/anvisa+aprova+medicamentos+ineditos+para+cancer+renal+e+doenca+pulmonar
http://www.fiercepharma.com/story/boehringer-trumpets-spiolto-quality-life-data-it-looks-its-niche-copd/2015-08-18
http://www.bloomberg.com/news/articles/2015-05-05/prescription-for-glaxo-a-new-boss-
http://www.bloomberg.com/news/articles/2015-02-04/glaxosmithkline-earnings-beat-estimates-on-hiv-cancer-drugs
http://www.prnewswire.com/news-releases/gsk-expands-its-portfolio-of-medicines-in-the-us-for-patients-with-asthma-and-copd-300025418.html
Market Place
Share 
